SecBot SecBot

EDIT

Editas Medicine, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001650664 Biotech & Drug DiscoveryGenomics & Gene Editing
$2.40 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $2.40
Market cap
$382.4M
Small cap
Consensus
Buy
68% Buy or better · 19 analysts
Median target
$5.50
+129% · range $1.00–15.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.21
1 year
−26.2%
from $3.25 · Oct 27
30 days
−4.4%
from $2.51
52-week range
$1.66–3.75
−36% from high · low Feb 5
Avg volume 20D
2.17M
Oct 8 spike 6.07M
Short interest
37.11M
≈24.2% of shares · +23.9%
Days to cover
9.3
at average volume
Insider net
−$92.1K
0 buyers · 3 sellers · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $92.1K.

  • InstitutionsBULLISH

    Q2 2026: 27 added (2 new), 8 trimmed or exited. Largest new: Ra Capital Management, $28.8M, Woodline Partners $11.5M.

  • AnalystsBULLISH

    13 of 19 rate it Buy or better. Median target $5.50 (+129%).

  • EstimatesRISING

    Current-quarter EPS estimate −$0.271 → −$0.206 over 90 days. 6 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +23.9% to 37.11M shares. 9.3 days to cover, ≈24.2% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$40.3M
in new stakes
FundMoveSharesValue
RA CAPITAL MANAGEMENT, L.P.NEW8,889,000$28.8M
VANGUARD CAPITAL MANAGEMENT LLCADD6,141,336$19.9M
Woodline Partners LPNEW3,555,497$11.5M
GOLDMAN SACHS GROUP INCDOUBLED2,614,036$8.5M
RENAISSANCE TECHNOLOGIES LLCTRIM2,468,919$8.0M
MARSHALL WACE, LLPDOUBLED2,037,287$6.6M
UBS Group AGADD750,763$2.4M
Nuveen, LLCTRIM521,213$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 68% rate it Buy or better
Strong Buy6Buy7Hold4Sell2Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies +129%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2026Wells Fargo
UPGRADE
UPGRADEOverweight
Sep 23, 2026Guggenheim
UPGRADE
UPGRADEBuy
Aug 18, 2026Ladenburg Thalmann
INITIATE
INITIATEBuy
May 5, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$92.1K
sold · 3 insiders
DateInsiderTypeValue
Sep 8, 2026
Ory Daniel Scott
EVP, Chief Medical Officer
AWARD950,000 sh
Sep 3, 2026
Parison Amy
SVP, Chief Financial Officer
SELL$1.4K
Sep 3, 2026
O'Neill Gilmore Neil
CEO
SELL$15.6K
Sep 3, 2026
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
SELL$2.2K
Aug 6, 2026
Ellinor Patrick Thomas II
Director
AWARD103,400 sh
Aug 3, 2026
Parison Amy
SVP, Chief Financial Officer
SELL$1.7K
Jul 28, 2026
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
SELL$13.2K
Jun 17, 2026
Levy Elliott M.
Director
AWARD51,700 sh

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.21
EPS estimate, this quarter
+24%
estimate change, 90 days
6↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.25–-$0.19+26.0%$4.5M
Next Q-$0.21-$0.28–-$0.08+12.7%$6.5M
Current FY-$0.83-$0.99–-$0.66+16.7%$25.8M
Next FY-$0.75-$0.85–-$0.60+19.6%$19.5M

Short side

FINRA· Sep 30, 2026
37,109,260
shares short
+23.9%
vs prior settlement
9.3
days to cover
≈24.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of…
8-K — Impact 6/10
Sep 30, 2026 Short interest report
Short Interest: EDIT up 24% to 37.1M shares
Settlement 2026-09-30 | Days to cover: 9.35 | ≈24.16% of shares outstanding (est.)
Sep 9, 2026 SEC
Editas Medicine's S-3 shelf registration (File No. 333-298665) became effective on September 8, 2026. This allows the…
EFFECT — Impact 4/10
Sep 8, 2026 Insider
Ory Daniel Scott was granted 950,000 shares
EVP, Chief Medical Officer
Sep 3, 2026 Insider
Parison Amy sold 453 shares
SVP, Chief Financial Officer @ $3.04 ($1.4K)
Sep 3, 2026 Insider
O'Neill Gilmore Neil sold 5,124 shares
CEO @ $3.04 ($15.6K)
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
8,889,000 shares ($28.8M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
6,141,336 shares ($19.9M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
EDIT Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Sep 30, 2026
Short interest
Short Interest: EDIT up 24% to 37.1M shares
Settlement 2026-09-30 | Days to cover: 9.35 | ≈24.16% of shares outstanding (est.)
Sep 8, 2026
Press release
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
Aug 31, 2026
Short interest
Short Interest: EDIT up 22% to 30.2M shares
Settlement 2026-08-31 | Days to cover: 8.96 | ≈19.69% of shares outstanding (est.)
Aug 5, 2026
Earnings
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027
Aug 5, 2026
Earnings date
EDIT Q2 2026 Earnings Scheduled — 2026-08-05

SecBot reports

12 filings · 4 press releases · 3 bullish · 4 bearish · 1 mixed · 4 neutral
All EDIT filing & press-release reports (16)